Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18897641 | 0.87 | MAOB (0.42) | MAOBDAOSLC2A1KDM1AKDM4E | |
| SCHEMBL22326393 | 0.87 | MAOB (0.42) | MAOBDAOSLC2A1KDM1AKDM4E | |
| SCHEMBL2738294 | 0.84 | DAO (0.43) | MAOBDAOSLC2A1KDM1AGNAI3 | |
| SCHEMBL20850613 | 0.84 | MAOB (0.40) | MAOBDAOSLC2A1KDM1AKDM4E | |
| SCHEMBL24309020 | 0.84 | MAOB (0.40) | MAOBDAOSLC2A1KDM1AKDM4E | |
| SCHEMBL22337368 | 0.83 | MAOB (0.39) | MAOBDAOSLC2A1KDM1AKDM4E | |
| SCHEMBL23489955 | 0.83 | MAOB (0.39) | MAOBDAOSLC2A1KDM1AGNAI3 | |
| SCHEMBL20254465 | 0.82 | DAO (0.46) | MAOBDAOSLC2A1KDM1ADRD2 | |
| SCHEMBL19630044 | 0.81 | GNAI3 (0.48) | GNAI3GNAO1GNAI1KDM4EUSP2 | |
| SCHEMBL7991668 | 0.81 | GNAI3 (0.48) | GNAI3GNAO1GNAI1KDM4ESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, CASP7 | MAOB 1646/4885DAO 4500/4885SLC2A1 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.